Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

1.

Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease.

Swaminath A, Bhadelia N, Wang YC.

Inflamm Bowel Dis. 2013 Oct;19(11):2444-9. doi: 10.1097/MIB.0b013e31829f008f.

PMID:
23945184
[PubMed - indexed for MEDLINE]
2.

Cost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil.

Steffen RE, Caetano R, Pinto M, Chaves D, Ferrari R, Bastos M, de Abreu ST, Menzies D, Trajman A.

PLoS One. 2013 Apr 4;8(4):e59546. doi: 10.1371/journal.pone.0059546. Print 2013.

PMID:
23593145
[PubMed - indexed for MEDLINE]
3.

Cost-effectiveness of different screening strategies (single or dual) for the diagnosis of tuberculosis infection in healthcare workers.

del Campo MT, Fouad H, Solís-Bravo MM, Sánchez-Uriz MA, Mahíllo-Fernández I, Esteban J.

Infect Control Hosp Epidemiol. 2012 Dec;33(12):1226-34. doi: 10.1086/668436. Epub 2012 Oct 25.

PMID:
23143360
[PubMed - indexed for MEDLINE]
4.

Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection.

Deuffic-Burban S, Atsou K, Viget N, Melliez H, Bouvet E, Yazdanpanah Y.

Int J Tuberc Lung Dis. 2010 Apr;14(4):471-81.

PMID:
20202306
[PubMed - indexed for MEDLINE]
5.

Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-α antagonist therapy.

Kowada A.

Mol Diagn Ther. 2010 Dec 1;14(6):367-73. doi: 10.2165/11586190-000000000-00000.

PMID:
21275454
[PubMed - indexed for MEDLINE]
6.

Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis.

Pooran A, Booth H, Miller RF, Scott G, Badri M, Huggett JF, Rook G, Zumla A, Dheda K.

BMC Pulm Med. 2010 Feb 22;10:7. doi: 10.1186/1471-2466-10-7.

PMID:
20170555
[PubMed - indexed for MEDLINE]
7.

Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany.

Diel R, Nienhaus A, Loddenkemper R.

Chest. 2007 May;131(5):1424-34.

PMID:
17494792
[PubMed - indexed for MEDLINE]
8.

Cost effectiveness of the interferon-γ release assay for tuberculosis screening of hemodialysis patients.

Kowada A.

Nephrol Dial Transplant. 2013 Mar;28(3):682-8. doi: 10.1093/ndt/gfs479. Epub 2012 Dec 13.

PMID:
23239835
[PubMed - indexed for MEDLINE]
9.

Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease.

van der Have M, Oldenburg B, Fidder HH, Belderbos TD, Siersema PD, van Oijen MG.

Dig Dis Sci. 2014 Mar;59(3):554-63. doi: 10.1007/s10620-013-2820-9. Epub 2013 Aug 15.

PMID:
23949640
[PubMed - indexed for MEDLINE]
10.

Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan.

Kowada A, Takahashi O, Shimbo T, Ohde S, Tokuda Y, Fukui T.

Mol Diagn Ther. 2008;12(4):235-51.

PMID:
18652520
[PubMed - indexed for MEDLINE]
11.

Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Shahidi N, Fu YT, Qian H, Bressler B.

Inflamm Bowel Dis. 2012 Nov;18(11):2034-42. doi: 10.1002/ibd.22901. Epub 2012 Jan 31.

PMID:
22294550
[PubMed - indexed for MEDLINE]
12.

Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening.

Kowada A.

Mol Diagn Ther. 2012 Jun 1;16(3):181-90. doi: 10.2165/11633610-000000000-00000.

PMID:
22594558
[PubMed - indexed for MEDLINE]
13.

Cost-optimisation of screening for latent tuberculosis in close contacts.

Diel R, Nienhaus A, Lange C, Schaberg T.

Eur Respir J. 2006 Jul;28(1):35-44. Epub 2006 Mar 29.

PMID:
16571615
[PubMed - indexed for MEDLINE]
14.

Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts.

Marra F, Marra CA, Sadatsafavi M, Morán-Mendoza O, Cook V, Elwood RK, Morshed M, Brunham RC, Fitzgerald JM.

Int J Tuberc Lung Dis. 2008 Dec;12(12):1414-24.

PMID:
19017451
[PubMed - indexed for MEDLINE]
15.

Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations.

Kowada A, Deshpande GA, Takahashi O, Shimbo T, Fukui T.

Mol Diagn Ther. 2010 Aug 1;14(4):229-36. doi: 10.2165/11538610-000000000-00000.

PMID:
20799765
[PubMed - indexed for MEDLINE]
16.

Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers.

de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH.

Arch Intern Med. 2009 Jan 26;169(2):179-87. doi: 10.1001/archinternmed.2008.524.

PMID:
19171815
[PubMed - indexed for MEDLINE]
17.

Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents.

Klein M, Jarosová K, Forejtová S, Bečvář R, Sedová L, Pavelka K, Simková G, Svobodová R, Hviscová K, Mann H, Půtová I, Vencovský J.

Clin Exp Rheumatol. 2013 Jan-Feb;31(1):111-7. Epub 2012 Oct 24.

PMID:
23101473
[PubMed - indexed for MEDLINE]
18.

The QuantiFERON-TB-GOLD assay for tuberculosis screening in healthcare workers: a cost-comparison analysis.

Fox BD, Kramer MR, Mor Z, Preiss R, Rusanov V, Fuks L, Peled N, Haim I, Raz M, Shitrit D.

Lung. 2009 Nov-Dec;187(6):413-9. doi: 10.1007/s00408-009-9182-2. Epub 2009 Oct 15.

PMID:
19830489
[PubMed - indexed for MEDLINE]
19.

Interferon-gamma releasing assay versus tuberculin skin testing for latent tuberculosis infection in targeted screening programs for high risk immigrants.

Orlando G, Merli S, Cordier L, Mazza F, Casazza G, Villa AM, Codecasa L, Negri E, Cargnel A, Ferrarese M, Rizzardini G.

Infection. 2010 Jun;38(3):195-204. doi: 10.1007/s15010-010-0015-2. Epub 2010 Apr 22.

PMID:
20411295
[PubMed - indexed for MEDLINE]
20.

Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.

Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, Hadziyannis E.

Clin Vaccine Immunol. 2011 Dec;18(12):2102-8. doi: 10.1128/CVI.05299-11. Epub 2011 Oct 12.

PMID:
21994356
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk